Oncothyreon (NASDAQ: onty) $ 106 (marketcap) Back in the game as Merck KGaA Re-start clinical trials

Oncothyreon (NASDAQ: Soto) is a Headquartered in Seattle specializing in biotechnology in the development of innovative therapeutic products for cancer treatment. overall objective of the company is developing and market new synthetic vaccines and targeted small molecules that have the potential to improve the lives of cancer patients and results. In early this year, teamed up with Germany-based Merck KGaA (MRCG.DE) for conducting clinical trials of a building immune therapy. There were two trials on lung cancer Start and Inspire call and a breast cancer study called Stride. Three tests, all of which involve BLP25 liposomal vaccine (Stimuvax) and is composed of a combination 2600 patients. On March 23, one of the patients developed brain inflammation Unexpected known as encephalitis, forcing the three pivotal trials in humans Merck to go on hold until researchers can determine if it really is safe to continue. Following this news, shares fell 27% Oncothyreon that day and did not resume.

Today Oncothyreon can breathe a sigh of relief. The company announced that its German partner has received FDA approval to reactivate two of three trials clinical vaccine Stimuvax cancer patients with lung cancer experimental, reviving hopes of a key pipeline drug. Phase III in cancer Breast stride remains suspended. In response to these new shares of the biotechnology company rose 6.9% in Frankfurt before Wall Street opened today. In Currently, the company trades at $ 4.11, up $ 0.50, or 13.85%.

Oncothyreon has not marketed the product, but it has other drugs of cancer in your portfolio, in addition to the basic BLP25 immune stimulant. Her partner, Merck, is primarily responsible for the development of this program, while Oncothyreon, This represents a large portion of the value investors assign to the company, is to collect royalties on sales if the treatment is effective.

"The resumption of the vaccination program clinical BLP25 liposomes is very good news for half of cancer patients and non-small cell lung cancer. If the principle and Inspire Phase III trials are successful, BLP25 Liposome vaccine could play an important role in the treatment of these patients are not being met "Said Dr. Frances Shepherd, Director of Medical Oncology, Princess Margaret Hospital in Toronto, Canada, and study investigator START Oncothyreon in a statement.

To read this article World Media, click the link below Market: http://www.worldmarketmedia.com/779/section.aspx/1870/post/oncothyreon-nasdaq-onty-106m-marketcap-back-in- the-game-as -Merck KGaA – re-start-clinical-trials

Disclosure: no positions

About the Author

About World Market Media:
WorldMarketMedia.com (The Global Online Investment Community) is a high traffic stock market, news data website providing cutting edge new media products and services to publicly traded companies worldwide. Our Editor’s Desk authors insightful real-time coverage on the economy, the capital markets and their listed companies.

Amgen News Mockumentary